PRNewswire

Record first quarter revenue of $355.7 million, up 37% year over yearRecord first quarter gross profit of $182.2 million, up 60% year over yearFirst quarter diluted EPS of $0.27, up 108% year over year

BOCA RATON, Fla., May 7, 2024 /PRNewswire/ -- Celsius Holdings, Inc. (Nasdaq: CELH), maker of CELSIUS®, the premium lifestyle energy drink formulated to power active lifestyles with ESSENTIAL ENERGY™, today reported record first quarter 2024 financial results.

... (continue reading...)

WUHAN, China, May 7, 2024 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that it will issue unaudited financial results for the first quarter ended March 31, 2024, on Tuesday,  May 14, 2024, before the market opens.  Management will conduct a conference call on May 14th at 8:00 A.M. EDT/8:00 P.M. Beijing Time to discuss these results.  A... (continue reading...)

RENO, Nev., May 7, 2024 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE: IAUX) ("i-80", or the "Company") is pleased to provide an update on planned programs at the Company's Granite Creek Property ("Granite Creek" or "the Property") located in Humboldt County, Nevada. This work being conducted in 2024 is expected to include definition and expansion drilling, underground development and test mining of the South Pacific Zone, and a Feasibility Study.

The primary... (continue reading...)

Deal supports firm's efforts to reach gender parity of partners by 2025

LAS VEGAS, May 7, 2024 /PRNewswire/ -- The AmeriFlex Group® -- a rapidly growing, advisor-owned hybrid RIA that puts financial planning first -- today announced the acquisition of The W Source™, a unique and innovative professional platform facilitating women-to-women networking opportunities across industries, on a local and national level. The W Source™ was co-founded by Hannah Buschbom,... (continue reading...)

• ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024
• Selected move-forward Phase 2 dose for IDE397 in MTAP squamous NSCLC, based on clinical efficacy observed in this indication, including multiple PRs by RECIST 1.1; and multiple PRs by RECIST 1.1 have also been observed in MTAP... (continue reading...)